País: Canadá
Língua: inglês
Origem: Health Canada
ETIDRONATE DISODIUM
COBALT PHARMACEUTICALS COMPANY
M05BA01
ETIDRONIC ACID
200MG
TABLET
ETIDRONATE DISODIUM 200MG
ORAL
14/100/500
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0113205002; AHFS:
CANCELLED PRE MARKET
2017-09-01
_ _ _ _ _Page 1 of 30_ PRODUCT MONOGRAPH Pr ETIDRONATE Etidronate Disodium Tablets(s) 200 mg and 400 mg USP Bone Metabolism Regulator, Anti-Pagetic Agent, Anti-Hypercalcemic Agent Manufactured by: Cobalt Pharmaceuticals Inc. 6500 Kitimat Road Mississauga, Ontario L5N 2B8 Date of Preparation: March 26, 2010 Control No. : 137100 _ _ _ _ _Page 2 of 30_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS..................................................................................5 ADVERSE REACTIONS....................................................................................................9 DRUG INTERACTIONS ..................................................................................................11 DOSAGE AND ADMINISTRATION..............................................................................12 OVERDOSAGE ................................................................................................................14 ACTION AND CLINICAL PHARMACOLOGY ............................................................15 STORAGE AND STABILITY..........................................................................................16 SPECIAL HANDLING INSTRUCTIONS .......................................................................16 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................17 PART II: SCIENTIFIC INFORMATION ...............................................................................18 PHARMACEUTICAL INFORMATION..........................................................................18 CLINICAL TRIALS....................................... Leia o documento completo